Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox

European Journal of Haematology

Volumn 92, Issue 6, 2014, Pages 521-526

  Taher, Ali T ^a   Porter, John B ^b   Viprakasit, Vip ^c   Kattamis, Antonis ^d   Chuncharunee, Suporn ^e   Sutcharitchan, Pranee ^f   Siritanaratkul, Noppadol ^c   Origa, Raffaella ^g   Karakas, Zeynep ^h   Habr, Dany ⁱ   Zhu, Zewen ⁱ   Cappellini, M Domenica ^j  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF ATHENS   (Greece)

^e MAHIDOL UNIVERSITY   (Thailand)

^f KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^g Evolutiva/Osp Reg Microcitemie ASL   (Italy)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Iron chelation; Iron overload; Thalassemia

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; DEFERASIROX; IRON; PLACEBO; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA THALASSEMIA; ANOREXIA; ARTICLE; BACKACHE; BETA THALASSEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EYE DISEASE; FAINTNESS; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; IRON CHELATION; IRON OVERLOAD; LETHARGY; LIVER LEVEL; MALE; NAUSEA; NON TRANSFUSION DEPENDENT THALASSEMIA; OROPHARYNX PAIN; PHARYNGITIS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SOMNOLENCE; THALASSEMIA; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; ADVERSE EFFECTS; BLOOD TRANSFUSION; COMPLICATION; LIVER; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

BENZOATES; BLOOD TRANSFUSION; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; THALASSEMIA; TREATMENT OUTCOME; TRIAZOLES;

EID: 84900489981     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12270     Document Type: Article

References (15)

1. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in b-thalassaemia intermedia. Lancet 1979;2:819-21.
2. Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharoen S, Charoenlarp P, Brittenham G, Pippard MJ, Finch CA. The effect of erythroid hyperplasia on iron balance. Blood 1988;71:1124-9.
3. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT. Elevated liver iron concentration is a marker of increased morbidity in patients with b-thalassemia intermedia. Haematologica 2011;96:1605-12.
4. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010;150:486-9.
5. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006;30:119-24.
6. Musallam KM, Motta I, Salvatori M, Fraquelli M, Marcon A, Taher AT, Cappellini MD. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with beta-thalassemia intermedia. Blood Cells Mol Dis 2012;49:136-9.
7. Taher AT, Porter J, Viprakasit V, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120:970-7.
8. Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol 2013;88:409-15.
9. Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics - EXJADE 125 mg, 250 mg, 500 mg dispersible tablets. 2013. Available at: http://www.medicines.org.uk/emc/medicine/18805/SPC/.
10. Thalassemia International Federation. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). 2013. Available at: http://www.thalassaemia.org.cy/wp-content/uploads/pdf/educational-programmes/Publications/Non-Transfusion%20Dependent%20Thalassaemias%20%282013%29/NTDT%20ENGLISH.pdf.
11. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 2013;92:1485-93.
12. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
13. Piga A, Fracchia S, Lai ME, Cappellini MD, Habr D, Wegener M, Bouillaud E, Forni GL. Two-year renal hemodynamic effects of deferasirox in patients with transfusion-dependent β-thalassemia. Blood 2012;120: abst 3257. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3257.
14. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010;148:466-75.
15. Taher A, Porter J, Viprakasit V, et al. Serum ferritin for predicting clinically relevant LIC thresholds to guide management of patients with non-transfusion-dependent thalassemia treated with deferasirox: THALASSA study extension analysis. Haematologica 2013;98 (Suppl 1):486 abst S1171.